Birgitte Klug Albertsen

Dr. Birgitte Klug Albertsen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in Blood
Verified
Journal Article
Closed access
PDF file
SHSofie Gottschalk Højfeldt
Sofie Gottschalk Højfeldt
KGKathrine Grell
Kathrine Grell
JAJonas Abrahamsson
Jonas Abrahamsson
BLBendik Lund
Bendik Lund
KVKim Vettenranta
Kim Vettenranta
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
Truncation of asparaginase treatment due to asparaginase related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase exposure among 1401 children aged 1-17 years, diagnosed with ALL between July 2008 and February 2016, and treated according to the NOPHO ALL2008 protocol including extended asparaginase exposure (1,000 IU/m2 intramuscularly weeks 5 to 33). Patients were included with delayed entry at their last administered asparaginase treatment or detection of SI and followed until relapse, death, secondary malignancy, or end of follow-up (median: 5.71 years, interquartile range: 4.02-7.64). In a multiple Cox model comparing patients with (n=358) and without (n=1043) truncated asparaginase treatment due to clinical toxicity, the adjusted relapse-specific hazard ratio (aHR) was 1.33 (95% confidence interval [CI]: 0.86-2.06, P=0.20). In a substudy including only patients with information on enzyme activity (n=1115), the 7-year cumulative incidence of relapse for the 301 patients with truncation of asparaginase treatment or SI (157 hypersensitivity, 53 pancreatitis, 14 thrombosis, 31 other, 46 SI) was 11.1% (95% CI: 6.9-15.4) versus 6.7% (95% CI: 4.7-8.6) for the 814 remaining patients. The relapse-specific aHR was 1.69 (95% CI: 1.05-2.74, P=0.03). The unadjusted bone-marrow relapse-specific HR was 1.83 (95% CI: 1.07-3.14, P=0.03) and 1.86 (95% CI: 0.90- 3.87, P=0.095) for any CNS relapse. These results emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparaginase therapy when feasible.

18 November 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SHSofie G. Højfeldt
Sofie G. Højfeldt
BWBenjamin O. Wolthers
Benjamin O. Wolthers
MTMorten Tulstrup
Morten Tulstrup
JAJonas Abrahamsson
Jonas Abrahamsson
RGRamneek Gupta
Ramneek Gupta
TGthe Nordic Society of Paediatric Haematology Oncology (NOPHO) group
the Nordic Society of Paediatric Haematology Oncology (NOPHO) group

29 June 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LHLouise Tram Henriksen
Louise Tram Henriksen
SHSofie Gottschalk Højfeldt
Sofie Gottschalk Højfeldt
KSKjeld Schmiegelow
Kjeld Schmiegelow
TFThomas Leth Frandsen
Thomas Leth Frandsen
PWPeder Skov Wehner
Peder Skov Wehner
NGNordic Society of Pediatric Hematology and Oncology, NOPHO Group
Nordic Society of Pediatric Hematology and Oncology, NOPHO Group

4 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
LLLsl Line Stensig Lynggaard
Lsl Line Stensig Lynggaard
CRCecilie Utke Rank
Cecilie Utke Rank
SHStefan Nygaard Hansen
Stefan Nygaard Hansen
SHSofie Gottschalk Højfeldt
Sofie Gottschalk Højfeldt
LHLouise Tram Henriksen
Louise Tram Henriksen
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized protocol compliance and compromises survival. We investigated the association between risk of asparaginase-associated toxicities (AspTox) and asparaginase enzyme activity (AEA) levels in 1155 children aged 1.0 to 17.9 years, diagnosed with ALL between July 2008 and March 2016, and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. Patients with ≥2 blood samples for AEA measurement drawn 14 ± 2 days after asparaginase administration were included (6944 trough values). AEA was measurable (or >0 IU/L) in 955 patients, whereas 200 patients (17.3%) had asparaginase inactivation and few AspTox recorded. A time-dependent multiple Cox model of time to any first asparaginase-associated toxicity adjusted for sex and age was used. For patients with measurable AEA, we found a hazard ratio (HR) of 1.17 per 100 IU/L increase in median AEA (95% confidence interval [CI], 0.98-1.41; P = .09). For pancreatitis, thromboembolism, and osteonecrosis, the HRs were 1.40 (95% CI, 1.12-1.75; P = .002), 0.99 (95% CI, 0.70-1.40; P = .96), and 1.36 (95% CI, 1.04-1.77; P = .02) per 100 IU/L increase in median AEA, respectively. No significant decrease in the risk of leukemic relapse was found: HR 0.88 per 100 IU/L increase in AEA (95% CI, 0.66-1.16; P = .35). In conclusion, these results emphasize that overall AspTox and relapse are not associated with AEA levels, yet the risk of pancreatitis and osteonecrosis increases with increasing AEA levels.

1 February 2022 in European Journal of Cancer
Verified
Journal Article
Open access
LBLeiah J. Brigitha
Leiah J. Brigitha
MFMarta Fiocco
Marta Fiocco
RPRob Pieters
Rob Pieters
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
GEGabriele Escherich
Gabriele Escherich
ISInge van der Sluis
Inge van der Sluis
Hypersensitivity reactions to asparaginase challenge its use and occur frequently (30-75%) after native Escherichia Coli (E.coli) asparaginase. Comparison of incidence of allergic reactions to pegylated E.coli asparaginase (PEGasparaginase) across contemporary paediatric acute lymphoblastic leukaemia (ALL) protocols is lacking. Questionnaires were sent to all members of the international ALL Ponte di Legno Toxicity Working Group. Meta-analyses were conducted to estimate the incidence of three types of hypersensitivity (allergy, allergic-like reaction and silent inactivation). Information on protocol level regarding PEGasparaginase dosing regimen, administration route and use of therapeutic drug monitoring was collected for risk analysis. Newly diagnosed patients with ALL (n = 5880), aged 1-24 years old, were enrolled in seven different upfront ALL protocols using PEGasparaginase as first-line treatment. The incidence of allergic reactions (sum of allergies and allergic-like reactions) [95% confidence interval] was 2% [1%; 3%] during induction and 8% [5%; 11%] during postinduction. Route of administration, number of doses, dosage and number of PEGasparaginase-free weeks did not significantly influence risk of hypersensitivity. Multivariate meta-regression analysis suggests that initiation of PEGasparaginase in postinduction and higher number of PEGasparaginase-free intervals increased the risk for allergic reactions. 9-16% and 23-29% of all hypersensitivities were allergic-like reactions and silent inactivation, respectively. The incidence of allergic reactions is lower in protocols using PEGasparaginase as first-line treatment compared with that reported for E.coli asparaginase or PEGasparaginase after E.coli asparaginase. Postinduction phase, a higher number of PEGasparaginase-free intervals, and initiation of PEGasparaginase in postinduction phase are risk factors for allergic reactions. These results are important for planning of PEGasparaginase administrations in future frontline therapy.

28 March 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
LLLine Stensig Lynggaard
Line Stensig Lynggaard
GVGoda Vaitkeviciene
Goda Vaitkeviciene
CLCecilia Langenskiöld
Cecilia Langenskiöld
ALAnne Kristine Lehmann
Anne Kristine Lehmann
PLPäivi M. Lähteenmäki
Päivi M. Lähteenmäki
BABirgitte Klug Albertsen
Birgitte Klug Albertsen